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ABSTRACT
Background The assessment of treatment response in
idiopathic pulmonary fibrosis (IPF) is complicated by the
variable clinical course. We examined the variability in
the rate of disease progression and evaluated the effect
of continued treatment with pirfenidone in patients who
experienced meaningful progression during treatment.
Methods The source population included patients
enrolled in the ASCEND and CAPACITY trials (N=1247).
Pearson’s correlation coefficients were used to
characterise the relationship between changes in FVC
during consecutive 6-month intervals in the placebo
population. Outcomes following a ≥10% decline in FVC
were evaluated by comparing the proportion of patients
in the pirfenidone and placebo groups who experienced
a ≥10% decline in FVC or death during the subsequent
6 months.
Results A weak negative correlation was observed
between FVC changes during consecutive intervals in the
placebo population (coefficient, −0.146, p<0.001),
indicating substantial variability. Thirty-four (5.5%) and
68 (10.9%) patients in the pirfenidone and placebo
groups, respectively, experienced a ≥10% decline in FVC
by month 6. During the subsequent 6 months, fewer
patients in the pirfenidone group compared with placebo
experienced a ≥10% decline in FVC or death (5.9% vs
27.9%; relative difference, 78.9%). There was one
(2.9%) death in the pirfenidone group and 14 (20.6%)
deaths in the placebo group (relative difference, 85.7%).
Conclusions Longitudinal FVC data from patients with
IPF showed substantial intrasubject variability,
underscoring the inability to reliably assess therapeutic
response using serial FVC trends. In patients who
progressed during treatment, continued treatment with
pirfenidone resulted in a lower risk of subsequent FVC
decline or death.
Trial registration numbers NCT01366209,
NCT00287729, NCT00287716.
INTRODUCTION
The recent regulatory approval of pirfenidone and
nintedanib marked an important milestone in the
decades long search for a safe and effective
treatment for idiopathic pulmonary fibrosis (IPF)—
a chronic, irreversible and almost uniformly fatal
lung disease characterised by worsening dyspnoea
and progressive pulmonary insufficiency.1 While
the emergence of proven therapeutic options for
patients with IPF is a welcome development, clini-
cians will now be confronted with a series of prac-
tical issues for which there are no available data to
guide clinical decision making. Chief among these
are the assessment of therapeutic response in the
individual patient and the management of patients
who experience meaningful progression of disease
despite therapeutic intervention.
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Key messages
What is the key question?
▸ To further inform clinical decisions regarding
the assessment and management of patients
with idiopathic pulmonary fibrosis, we sought
to characterise the variability in the rate of
disease progression and evaluate the effect of
continued treatment with pirfenidone in
patients who experience meaningful
progression during treatment.
What is the bottom line?
▸ In patients with idiopathic pulmonary fibrosis
who experienced a ≥10% absolute decline in
FVC during the first 6 months of treatment,
continued treatment with pirfenidone reduced
the risk of a second ≥10% decline in FVC or
death compared with placebo.
Why read on?
▸ Our findings provide the first available evidence
to suggest that continued treatment with
pirfenidone may confer a benefit to patients
with idiopathic pulmonary fibrosis who exhibit
evidence of meaningful disease progression
during treatment.
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The clinical efficacy and safety of pirfenidone and nintedanib
in patients with IPF were demonstrated in three and two multi-
national phase 3 trials, respectively.2–4 The primary clinical effi-
cacy end point in each of these trials was the change from
baseline in forced vital capacity (FVC), a widely used test that
has been shown to be a reliable, valid and responsive measure
of disease status and an independent predictor of mortality in
patients with IPF.5–11 However, while the favourable test per-
formance characteristics of FVC make it a suitable end point for
randomised controlled trials, considerable intersubject and intra-
subject variability may be observed in the rate of FVC decline in
patients with IPF.1 12 As a result, the clinical assessment of
disease progression and therapeutic response in an individual
patient represents a distinct challenge.
In the present exploratory analysis, we sought to characterise
the variability in the rate of disease progression in IPF by com-
paring the change in FVC during two consecutive 6-month
intervals in the pooled placebo population from the phase 3
multinational trials evaluating pirfenidone. To further inform
the management of patients who experience meaningful pro-
gression during treatment, we then performed a post hoc
exploratory analysis of outcomes following 6 months of contin-
ued treatment with pirfenidone or placebo in patients who
experienced a ≥10% decline in FVC during the first 6 months
of treatment in the phase 3 trials.
METHODS
Patients
The source population included all patients randomised to treat-
ment with pirfenidone 2403 mg/day or placebo in the
CAPACITY or ASCEND studies. Eligibility criteria for these
studies have been described elsewhere.2 3 For assessments of
FVC variability, the analysis population included all patients ran-
domised to placebo in CAPACITY or ASCEND. Treatment out-
comes following a clinically meaningful decline in FVC were
evaluated in the pooled pirfenidone 2403 mg/day and placebo
populations from the CAPACITY and ASCEND studies.
Study design
Figure 1 depicts the study design for the two components of the
study. To characterise the variability in the rate of disease pro-
gression, the change in per cent predicted FVC (%FVC) from
baseline to month 6 was compared with the change from month
6 to month 12 in the pooled placebo population from the
CAPACITY and ASCEND studies. To examine the effect of con-
tinued treatment following a clinically meaningful decline in
FVC, all patients in the pooled pirfenidone 2403 mg/day and
placebo groups from the CAPACITY and ASCEND studies who
experienced a ≥10% absolute decline in %FVC during the
initial observation period were selected for inclusion in the ana-
lysis of outcomes during the subsequent 6-month assessment
period. For patients who experienced an initial ≥10% decline in
%FVC by the month 3 study visit, subsequent outcomes were
assessed between the month 3 and month 9 study visits; for
those who experienced an initial decline between the month 3
and month 6 study visits, subsequent outcomes were assessed
between the month 6 and month 12 study visits.
In each of the trials included in the analyses, eligible patients
were randomised to treatment with oral pirfenidone 2403 mg/
day or placebo. Study drug was administered in three equally
divided daily doses for either 1 year (ASCEND) or a minimum
of 72 weeks (CAPACITY). Clinical efficacy outcomes were mea-
sured at baseline and at 3-month intervals in each trial.
Spirometry was performed in accordance with standard
American Thoracic Society (ATS) guidelines in all three studies;
results were reviewed centrally in the ASCEND and locally in
the CAPACITY studies.
Statistical analysis
For assessments of FVC variability, categorical shift analysis and
Pearson’s correlation coefficients were used to characterise the
relationship between longitudinal changes in %FVC during two
consecutive 6-month intervals in the pooled placebo population.
For the latter, the strength of the relationship was designated
according to Cohen’s criteria as follows: >0.5, large; 0.5–0.3,
moderate; 0.3–0.1, small; and <0.1, trivial.13 To further assess
the relationship between changes in %FVC in the first and
second 6-month intervals, a weighted κ coefficient was calcu-
lated for the following categories of change: stable or improved,
0% to <5% decline, ≥5% to <10% decline and ≥10% decline.
Spaghetti plots of the change in %FVC from baseline to 1 year
were also constructed for a randomly selected sample of 50
patients from the pooled placebo population from the
CAPACITY and ASCEND studies. The random sample was gen-
erated using SAS software, V.9.2 (SAS Institute).
The stability of two temporally proximate measures of FVC
was assessed using Pearson’s correlation coefficients for the two
assessments of %FVC performed on separate days as part of the
final study visit (week 52A and week 52B in the ASCEND study
and week 72A and week 72B in the CAPACITY studies). The
strength of the relationship was designated according to
Cohen’s criteria as noted.
Treatment outcomes following a clinically meaningful decline
in FVC were evaluated in patients from the pooled pirfenidone
and placebo populations who experienced a ≥10% absolute
decline in %FVC by the month 3 or month 6 study visits. The
primary analysis compared the proportion of patients in each
treatment group who experienced any of the following during
the subsequent 6 months: (1) ≥10% absolute decline in %FVC
or death; (2) no further decline in %FVC; or (3) death. To min-
imise bias, patients who discontinued study treatment were
included in the analysis. Absolute change in %FVC during the
first 3 months or 6 months was based on observed data only.
For the subsequent 6-month assessment period, missing %FVC
values due to death were assigned to the worst category for the
categorical analysis and replaced with the worst possible value
(%FVC=0) for measures of central tendency. Missing values
due to reasons other than death were replaced with the average
value from the three patients with the least sum of squared dif-
ferences (SSD) across study visits. Categorical differences
between treatment groups were evaluated using a two-sided
Fisher’s exact test.
The change in %FVC during the 6-month period following
an initial decline was also evaluated in the pooled pirfenidone
and placebo groups using a rank analysis of covariance model.
Missing values due to death were assigned the worst ranks
according to time of death and missing values due to reasons
other than death were imputed using the SSD methodology.
Data are presented as median (range) values.
An on-treatment analysis evaluated outcomes in the subset of
patients who remained on study treatment during the 6-month
period following an initial ≥10% absolute decline in %FVC.
Patients were considered to have remained on treatment if they
had not discontinued treatment before the end of the second
6-month observation period. Patients with missing data due to
death were considered to have remained on treatment if the last
dose of study drug was within 28 days of death.
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FVC and mortality outcomes following hospitalisation were
evaluated in patients in the pooled pirfenidone and placebo
groups who were hospitalised due to any cause within the first
6 months of study treatment. Outcomes were assessed during
the 6-month period beginning with the first scheduled study
visit following the date of hospitalisation.
RESULTS
A total of 1247 patients met the criteria for enrolment in the
CAPACITY or ASCEND studies and were assigned to treatment
with pirfenidone 2403 mg/day (N=623) or placebo (N=624).
Demographics and baseline characteristics for the pooled pirfe-
nidone and placebo groups are summarised in online supple-
mentary table S1.
FVC change in the placebo population
Categorical shift analysis of change in %FVC during two con-
secutive 6-month intervals in the pooled placebo group showed
marked variability in the magnitude of change during the first
and second observation periods (table 1; see online supplemen-
tary figure S1). A total of 59 (9.5%) patients experienced a
≥10% decline in FVC between baseline and month 6; of these,
Figure 1 Study profile. (A) Assessment of FVC variability. (B) Assessment of treatment outcomes following a ≥10% absolute decline in FVC.
Table 1 Categorical shift analysis of absolute change in per cent predicted FVC during two consecutive 6-month intervals in the pooled
placebo population
Patients, n (%)*
Month 6 to month 12
FVC stable or improved FVC decline >0 to <10% FVC decline ≥10% Death Missing† Total, n
Baseline to month 6 FVC stable or improved 32 (19.8) 102 (63.0) 19 (11.7) 2 (1.2) 7 (4.3) 162
FVC decline >0 to <10% 117 (31.7) 213 (57.7) 17 (4.6) 6 (1.6) 16 (4.3) 369
FVC decline ≥10% 16 (27.1) 17 (28.8) 7 (11.9) 13 (22.0) 6 (10.2) 59
Death 0 0 0 19 (100) 0 19
Missing† 0 0 0 1 (6.7) 14 (93.3) 15
Total, n 165 332 43 41 43 624
*Percentages represent proportion of patients in the same row.
†Missing due to reasons other than death.




 10 April 2019 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2015-207011 on 11 March 2016. Downloaded from 
16 (27.1%) had stable or improved FVC values during the sub-
sequent 6 months. Conversely, of the 162 (26.0%) patients who
had stable or improved FVC values between baseline and month
6, 121 (74.7%) experienced a decline in FVC during the subse-
quent 6 months, including 19 (11.7%) patients who experi-
enced a ≥10% decline. Shift analysis of absolute change in
%FVC oneline using 5% categorical thresholds, as well as rela-
tive (rather than absolute) change in %FVC showed similar vari-
ability (see online supplementary tables S2 and S3, respectively).
A weak negative correlation was observed between changes in
%FVC during two consecutive 6-month intervals (correlation
coefficient, −0.146, p<0.001; figure 2), indicating substantial
variability in both the magnitude and direction of change.
Additionally, FVC change during the first interval was not pre-
dictive of change during the second interval (weighted κ coeffi-
cient, −0.024; 95% CI −0.084 to 0.037). A sensitivity analysis
using relative (rather than absolute) change in %FVC yielded
similar results (Pearson’s correlation coefficient, 0.034,
p=0.426; weighted κ coefficient, −0.039; 95% CI −0.101 to
0.023).
The spaghetti plot depicted in figure 3 shows the change in
%FVC from baseline to 1 year in a randomly selected sample of
50 patients from the pooled placebo population. While the
general trend was characterised by a marginal overall decline in
lung volume, there was substantial intersubject and intrasubject
variability in both the magnitude and direction of change.
Treatment outcomes following evidence of disease
progression
A total of 34 (5.5%) and 68 (10.9%) patients in the pooled pir-
fenidone and placebo groups, respectively, experienced a ≥10%
absolute decline in %FVC between baseline and month 6 (rela-
tive difference, 49.5%; p<0.001). The initial decline occurred
by month 3 in 14 (2.2%) patients in the pirfenidone group and
24 (3.8%) patients in the placebo group, and between month 3
and month 6 in 20 (3.2%) and 44 (7.1%) patients in the pirfeni-
done and placebo groups, respectively.
Analysis of outcomes during the subsequent 6-month period
showed that fewer patients in the pirfenidone group compared
with placebo experienced a second ≥10% decline in %FVC or
death (2/34 (5.9%) in the pirfenidone group vs 19/68 (27.9%)
in the placebo group; relative difference, −78.9%; p=0.009),
and more patients in the pirfenidone group compared with
placebo had no further decline in %FVC (20/34 (58.8%) vs 26/
68 (38.2%); relative difference, 53.8%; p=0.059; table 2).
There was 1 death among 34 patients (2.9%) in the pirfenidone
group and 14 deaths among 68 patients (20.6%) in the placebo
group (relative difference, −85.7%; p=0.018). Similar results
were observed among patients who experienced an initial FVC
decline by month 3 compared with those who experienced an
initial decline between month 3 and month 6 (see online
supplementary tables S4 and S5). Additionally, sensitivity ana-
lyses using alternative methods for handling missing data
showed a consistent treatment effect across analyses (see online
supplementary tables S6 and S7), as did the analysis of out-
comes using relative (rather than absolute) change in %FVC (see
online supplementary table S8).
The on-treatment analysis also yielded similar findings (see
online supplementary table S9). A total of 24/34 (70.6%) and
60/68 (88.2%) patients in the pirfenidone and placebo groups,
respectively, remained on treatment during the 6-month period
following an initial ≥10% decline in %FVC. Of these, 1 (4.2%)
patient in the pirfenidone group and 15 (25.0%) patients in the
placebo group experienced a second ≥10% decline in %FVC or
death (relative difference, −83.3%; p=0.032). No further
decline in %FVC was observed in 14 (58.3%) patients in the
pirfenidone group compared with 22 (36.7%) patients in the
placebo group (relative difference, 59.1%; p=0.089). There
were no deaths in the pirfenidone group and 10 (16.7%) deaths
in the placebo group during the 6 months following the initial
decline in FVC (relative difference, −100%; p=0.056).
Figure 2 Relationship between changes in per cent predicted FVC
during two consecutive 6-month intervals*. *Pooled placebo
population, CAPACITY and ASCEND studies (N=540).
Figure 3 Spaghetti plot of change from baseline to 1 year in per cent
predicted FVC*. *Randomly selected patients from the pooled placebo
population from the CAPACITY and ASCEND studies (N=50).
Table 2 Outcomes after 6 months of continued treatment










in FVC or death
2 (5.9%) 19 (27.9%) −78.9 0.009
No further
decline in FVC‡
20 (58.8%) 26 (38.2%) 53.8 0.059
Death 1 (2.9%) 14 (20.6%) −85.7 0.018
*Initial decline in per cent predicted FVC ≥10% occurring during the first 3 months
or 6 months of study treatment.
†Fisher’s exact test.
‡Either no decline or increase in FVC.
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The median change in %FVC during the 6-month period fol-
lowing an initial ≥10% decline was 1.1% (range, −84.6, 16.2)
in the pirfenidone group and −3.0% (range, −67.3, 13.0) in the
placebo group (p=0.025; figure 4). In the on-treatment analysis,
the median change in %FVC was 2.1% (range, −10.6, 16.2)
and −3.0% (range, −59.1, 13.0) in the pirfenidone and placebo
groups, respectively (p=0.154).
Treatment outcomes following hospitalisation
A total of 44 (7.1%) and 49 (7.9%) patients in the pooled pirfe-
nidone and placebo groups, respectively, were hospitalised due
to any cause between baseline and month 6. Among these, 4
(9.1%) patients in the pirfenidone group and 16 (32.7%)
patients in the placebo group experienced a ≥10% decline in
%FVC or death during the subsequent 6-month observation
period (relative difference, −72.2%; table 3). The median
change in %FVC during this period was −1.8% (range, −56.3,
11.5) in the pirfenidone group and −4.2% (range, −80.6, 8.3)
in the placebo group. There were 2 (4.5%) deaths in the pirfeni-
done group compared with 14 (28.6%) deaths in the placebo
group during the second 6-month assessment period. Seven
(1.1%) and 15 (2.4%) patients in the pirfenidone and placebo
groups, respectively, experienced both a ≥10% decline in FVC
and hospitalisation between baseline and month 6 (Pearson’s
correlation coefficients, 0.086 and 0.101 in the pirfenidone and
placebo groups, respectively). Among these, there were no deaths
in the pirfenidone group and four (26.7%) deaths in the placebo
group during the subsequent 6-month period; however, the
limited number of events precludes meaningful interpretation.
DISCUSSION
The emergence of the first safe and efficacious therapies for
patients with IPF heralds the dawn of a new era in the treatment
of this devastating disease. However, while both pirfenidone
and nintedanib have been proven to significantly reduce the
decline in lung function in patients with IPF, neither agent is a
cure, and aggregate data from large, randomised, controlled
trials demonstrate that patients will likely continue to experi-
ence disease progression despite therapeutic intervention.
Therefore, clinicians will be confronted with two important
questions. First, what constitutes evidence of an inadequate clin-
ical response to therapy and, second, how should such patients
be managed?
To further inform clinical decisions related to the assessment
and management of patients who experience meaningful pro-
gression during treatment, we analysed pooled data from a large
and well-defined population of patients with IPF who were fol-
lowed prospectively for at least 1 year. Our analyses yielded two
important observations with implications for the clinical assess-
ment and management of patients with IPF. First, disease pro-
gression—as measured by longitudinal change in FVC—is
highly variable and cannot be predicted based on prior trends.
Analysis of longitudinal FVC data showed a weak inverse correl-
ation between changes in FVC during two consecutive 6-month
intervals, highlighting the variability in both the magnitude and
direction of change in this prospective, clinical trial population.
These results are similar to observations from a retrospective ana-
lysis of a real-world IPF cohort, which suggested that FVC decline
in the first year of follow-up after diagnosis was not predictive of
future declines in physiology.14 The consistency of the findings in
two different populations, each of which is subject to a different
type of bias, strengthens the observations from both studies.
Importantly, these findings also demonstrate that in an individual
patient comparison of serial pulmonary function trends during the
intervals preceding and following initiation of therapy is not a reli-
able method of assessing therapeutic response. Clinical decisions
related to therapeutic efficacy should therefore be guided by aggre-
gate data from prospective, randomised, controlled trials.
Second, in patients who exhibit clinically meaningful progres-
sion of disease during treatment, our findings show that continued
treatment with pirfenidone may reduce the risk of a subsequent
≥10% decline in FVC or death. This observation is particularly
relevant to clinicians given the absence of data regarding second-
line treatment strategies. While sequential monotherapy and com-
bination therapy are common strategies for patients who have a
suboptimal response to therapy in other pulmonary diseases, no
such data yet exist in patients with IPF.15 Until such data are avail-
able, our findings provide the first available evidence to suggest
that continuing treatment with pirfenidone despite evidence of
disease progression confers a meaningful benefit. We observed a
78.9% reduction in the proportion of patients with a second
≥10% decline in FVC or death and an 85.7% reduction in the
proportion of patients who died during the 6 months following
an initial FVC decline in the pirfenidone group compared with
placebo. A similar treatment effect was observed during the
6 months following hospitalisation; although there was some col-
linearity observed between hospitalisation and FVC decline, the
majority of patients were unique. While the sample size was rela-
tively small, the large magnitude of treatment effect observed in
our analyses suggests that pirfenidone might have an important
role in the management of patients with progressive disease.











in FVC or death
4 (9.1%) 16 (32.7%) −72.2 0.010
No further
decline in FVC‡
15 (34.1%) 12 (24.5%) 39.2 0.364
Death 2 (4.5%) 14 (28.6%) −84.3 0.002
*All-cause hospitalisation between baseline and month 6; treatment outcomes
assessed during the 6-month interval beginning with the first study visit following the
date of hospitalisation.
†Fisher’s exact test.
‡Either no decline or increase in FVC.
Figure 4 Median change in per cent predicted FVC during the
6-month period following an initial decline in FVC ≥10%. *Rank
analysis of covariance with ranked change from baseline as the
outcome variable; study, treatment, and region as fixed effects; and
ranked baseline FVC as a covariate. Deaths are ranked worst according
to time until death.
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A major goal of therapy in patients with IPF is to attenuate
the decline in lung function.16 17 Inherent in this goal is the
assumption that one can predict the expected rate of decline
based on prior trends and measure therapeutic response against
the expected rate of decline. However, as our results demon-
strate, the markedly variable clinical course observed in patients
with IPF precludes any such assumption. In light of this
dilemma, it might be suggested that the threshold of a 10%
decline in FVC that was used in the categorical assessment of
outcomes in the recent phase 3 trials could serve as a bench-
mark for defining treatment failure in the clinical setting.
A ≥10% decline in FVC has been shown in multiple studies
to be an independent predictor of mortality,6–11 and a change
of this magnitude is well above the estimated minimal clinic-
ally important difference in patients with IPF.5 Additionally,
the 2011 guidelines for the diagnosis and management of IPF
published by an expert committee endorsed by ATS/European
Respiratory Society (ERS)/Latin American Thoracic
Association (ALAT)/Japanese Respiratory Society (JRS) identi-
fied an absolute decline in per cent predicted FVC greater
than 10% as evidence of meaningful disease progression.1 It
should be noted, however, that while a decline of this magni-
tude is incontestably clinically meaningful, it is not necessarily
evidence of treatment failure, as one cannot preclude the pos-
sibility that an even greater decline might have been observed
in the absence of treatment or that treatment might impart a
benefit that is not captured by change in FVC. Moreover, as
our results suggest, continued treatment might confer subse-
quent benefits in terms of a decreased risk of further FVC
decline or death.
There are certain limitations to our analysis. First, while tem-
porally proximate measures of FVC demonstrated high
test-retest reproducibility, the contribution of measurement
error to the observed variability in FVC change over longer
periods cannot be precisely defined. Accordingly, the degree to
which the observed variability reflects true variability in the clin-
ical course is uncertain. We note, however, that this distinction
is largely academic, as the clinical implication of the observed
variability in FVC change remains the same regardless of the
relative contribution of measurement error. Specifically, variabil-
ity in the rate of change in FVC precludes the ability to reliably
predict the expected rate of change during subsequent periods
based on prior trends. As a result, therapeutic response cannot
be evaluated in an individual patient by comparing serial pul-
monary function trends during the intervals preceding and fol-
lowing the initiation of treatment. A strength of our current
analysis is that we evaluated individual patient data rather than
population-based means, which enabled greater insight into this
variability. Second, we selected FVC and hospitalisation as mea-
sures of initial disease progression because they are readily and
reliably ascertainable in virtually all patients in the typical clin-
ical setting. We did not evaluate outcomes following evidence of
disease progression based on other measures like 6-min walk
distance or diffusing capacity for carbon monoxide (DLCO); the
effect of continued treatment following meaningful decrements
in these and other measures is therefore not known. Finally, the
analysis of outcomes following evidence of disease progression
was a post hoc exploratory analysis; accordingly, the results
should be interpreted with caution.
In conclusion, analysis of longitudinal FVC data from a large
cohort of patients with IPF demonstrated high intersubject and
intrasubject variability in the rate of disease progression, under-
scoring the inability to reliably assess therapeutic response in an
individual patient based on serial FVC trends. In patients who
experienced a ≥10% decline in FVC or hospitalisation, contin-
ued treatment with pirfenidone resulted in a lower risk of FVC
decline or death during the subsequent 6 months. These find-
ings suggest a potential benefit to continued treatment with pir-
fenidone in patients with IPF who experience disease
progression during therapy.
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